Centrexion Therapeutics Begins U.S. IPO Effort

CNTX intends to raise $86.25 million in gross proceeds from an IPO of its common stock, not including customary underwriter options. No existing shareholders have indicated an interest to purchase shares of the IPO, although I would expect to see some investor support for the IPO since this is typical in the current IPO environment for life science firms.

This entry was posted in Recent Development News: Q3 - 2018, Recent Developments. Bookmark the permalink.
Read Full Article »